TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06734949

Intervention type: OTHER
Intervention: AI-guided patient classification
Description: The intervention consist in firstly obtaining clinical, genetic, histopathological, MRI data from total 500 patients coming from the defined Cohorts. The adaptative AI-tool developed, based on data provided, will then identify multi-modal characteristics that will support patients' superclusters and their multi-omics signatures.

Intervention type: OTHER
Intervention: AI-guided patient classification
Description: The intervention consist in firstly obtaining clinical, genetic, histopathological, MRI data from total 500 patients coming from the defined Cohorts. The adaptative AI-tool developed, based on data provided, will then identify multi-modal characteristics that will support patients' superclusters and their multi-omics signatures.

Intervention type: OTHER
Intervention: AI-guided patient classification
Description: The intervention consist in firstly obtaining clinical, genetic, histopathological, MRI data from total 500 patients coming from the defined Cohorts. The adaptative AI-tool developed, based on data provided, will then identify multi-modal characteristics that will support patients' superclusters and their multi-omics signatures.
Study: NCT06734195

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexmedetomidine + propofol
Description: Comparison of caudal dexmedetomidine + propofol sevoflurane-related emergence agitation in children undergoing congenital hernia repair.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol alone
Description: 30 patients will receive propofol 1mg/kg before the start of skin closure, administered over 10 minutes and caudal block using 1 ml/kg of bupivacaine 0. 25 % plus 2 ml normal saline.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: patients will receive caudal dexmedetomidine block using 1 ml/kg of bupivacaine 0. 25 % mixed with dexmedetomidie 1mic/kg diluted in 2 ml normal saline
Study: NCT06736093

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D3
Description: Vitamin D3 60,000 IU given once weekly Pre Liver Transplant atleast for 6 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsules once weekly for atleast 6 weeks pre liver transplant
Study: NCT06145516

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive behavioral therapy for insomnia (CBT-I)
Description: Hybrid CBT-I (self-guided digital format focusing on sleep restriction therapy and stimulus control + telehealth video-consultations with psychologist)

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Sleep education therapy (SET)
Description: Self-guided digital sleep education (sleep hygiene, sleep physiology, sleep disturbances etc) + telehealth video-consultations with research nurse
Study: NCT04640974

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cingal
Description: Single injection into the ankle joint of a 4 ml unit dose of Cingal containing 88 mg (22 mg/ml) of cross-linked sodium hyaluronate and 18 mg (4.5 mg/ml) of triamcinolone hexacetonide (TH).
Study: NCT05639413

Intervention type: OTHER
Group type: OTHER
Intervention: Collection of blood samples
Description: A 30 mL blood samples (6 mL in each of 5 EDTA tubes) will be collected from each patient at each timepoint.
Study: NCT05894265

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ActiveMatrix® Dosage A
Description: This group will receive ActiveMatrix® (AM) product dosage A (1cc AM diluted to 3cc with saline)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ActiveMatrix® Dosage B
Description: Group 2 will receive ActiveMatrix® product dosage B (2cc AM diluted to 3cc with saline)

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Saline injection
Description: Group 3 will receive saline injection
Study: NCT06217094

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NP-101 (3 g)
Description: Subjects will be assigned to take 3 g of NP-101 orally once daily for 28 days pre Y-90 treatment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NP-101 (4.8 g)
Description: Subjects will be assigned to take 4.8 g of NP-101 orally once daily for 28 days pre Y-90 treatment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NP-101 (6 g)
Description: Subjects will be assigned to take 6 g of NP-101 orally once daily for 28 days pre Y-90 treatment.
Study: NCT04830592

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NG-641
Description: Patients receive three doses of NG-641 by intravenous infusion. NG-641 is a replication competent adenoviral vector producing a bispecific T cell activator (TAc) targeting fibroblast activation protein (FAP) plus immune enhancer genes CXCL9/CXCL10/IFNa2. This can lead to killing of tumor cells and stimulation of immunity against the tumor cells.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NG-641
Description: Patients receive three doses of NG-641 by intravenous infusion. NG-641 is a replication competent adenoviral vector producing a bispecific T cell activator (TAc) targeting fibroblast activation protein (FAP) plus immune enhancer genes CXCL9/CXCL10/IFNa2. This can lead to killing of tumor cells and stimulation of immunity against the tumor cells.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Patients receive three doses of NG-641 by intravenous infusion and a single dose of Pembrolizumab by intravenous infusion.
Study: NCT06476314

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual Reality Glasses Group
Description: Apart from the routine clinic procedure, VR video scenes (contain nature views) will be watched for 5-10 minutes during the procedure.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Stress Ball Group
Description: Apart from the routine clinic procedure, it will be asked squeezing the stress ball for about 5-10 minutes (squeezing it once every time he counts to five)during the procedure.
Study: NCT05546450

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diet
Description: Patient in Diet Group and Cornus mas L. and Diet Group will be given a personalized diet and be followed up by a dietician.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diet
Description: Patient in Diet Group and Cornus mas L. and Diet Group will be given a personalized diet and be followed up by a dietician.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Cornus mas L.(Cornelian Cherry)
Description: Patients in Cornus mas L. Group and Cornus mas L. and Diet Group will receive 30 g/day freeze-dried Cornus mas L. fruit powder supplement.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Cornus mas L.(Cornelian Cherry)
Description: Patients in Cornus mas L. Group and Cornus mas L. and Diet Group will receive 30 g/day freeze-dried Cornus mas L. fruit powder supplement.
Study: NCT05726539

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Group-based peer support
Description: Receipt of semi-structured curriculum based group peer support that addresses common concerns of military spouses
Study: NCT06224309

Intervention type: DIAGNOSTIC_TEST
Intervention: 18F-BL40 PET/CT
Description: Vital signs will be recorded prior to the BL40 injection. Each study subject will have an intravenous catheter inserted. Prior to the radiotracer injection an ultra low dose CT will be taken. Subjects are positioned supine, arms down. The subject will receive a bolus intravenous dose of the 18F-BL40 from an approved study supplier site. A Dynamic PET scan will be taken of the heart. Then a serial whole body PET scan will be done. Vital signs will be taken again and the subject will have a bathroom break. The patient will return to the scanner bed for a standard low dose CT and whole body PET scan. Vital signs will be taken again, and subject will be allowed to use the washroom again. The subject will return to the scanner bed for the final time for an ultra low dose CT and whole body PET scan. A final set of vitals will be taken and the subject will be discharged.

Intervention type: DIAGNOSTIC_TEST
Intervention: 18F-FDG PET/CT
Description: The patient will return on another day for the 18F-FDG PET/CT scan. A fasting period of 6 hours is required before this scan.~Each study subject will have an intravenous catheter inserted. The subject will receive a bolus intravenous dose of the radiotracer from an approved study supplier site.~The subject will rest in a comfortable chair for 60 minutes. The subjects will then be taken to a designated washroom and asked to void prior to being scanned in order to clear excreted radiotracer activity from the urinary tract.~Subjects are positioned supine, arms down, and centered on the scanner bed and the PET/CT images will be acquired.

Intervention type: DIAGNOSTIC_TEST
Intervention: Routine Blood Draw - Phase 1 only
Description: Complete blood counts and routine clinical chemistry performed before and repeated within 18-72 hours after 18F-BL40 administration.
Study: NCT05149183

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: cervical stability training
Description: cervical stability training will be contain three phases, each phase has six positions ( supine, forearms, sidelying, four point kneeling, sitting and standing position)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: traditional treatment
Description: TENS, hot packs, stretching exercise of superficial neck muscles, and postural advice.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: traditional treatment
Description: TENS, hot packs, stretching exercise of superficial neck muscles, and postural advice.
Study: NCT05867082

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neural Mobilization
Description: Radial Nerve Mobilization, Medial Mobilization, Ulnar Mobilization

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neural Mobilization
Description: Radial Nerve Mobilization, Medial Mobilization, Ulnar Mobilization
Study: NCT06426485

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toludesvenlafaxine Hydrochloride Sustained-release Tablets
Description: orally once a day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: orally once a day
Study: NCT05934162

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Therapist-supported internet-delivered prolonged exposure
Description: 10 weeks of therapist-supported internet-delivered prolonged exposure

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Therapist-supported internet-delivered CBT
Description: 10 weeks of therapist-supported internet-delivered CBT
Study: NCT04764851

Intervention type: DRUG
Group type: OTHER
Intervention: ecopipam HCl ~2mg/kg/day
Description: oral tablet

Intervention type: DRUG
Group type: OTHER
Intervention: ecopipam HCl ~2mg/kg/day
Description: oral tablet

Intervention type: DRUG
Group type: OTHER
Intervention: ecopipam HCl ~2mg/kg/day
Description: oral tablet

Intervention type: COMBINATION_PRODUCT
Group type: OTHER
Intervention: Cohort 1 Probe Cocktail
Description: dextromethorphan, caffeine, omeprazole, and midazolam

Intervention type: COMBINATION_PRODUCT
Group type: OTHER
Intervention: Cohort 2 Probe Cocktail
Description: dabigatran, pitavastatin, rosuvastatin, atorvastatin, midazolam

Intervention type: COMBINATION_PRODUCT
Group type: OTHER
Intervention: Cohort 3 Probe Cocktail
Description: bupropion
Study: NCT04900558

Intervention type: PROCEDURE
Intervention: Radical Cystectomy
Description: All the patients enrolled have undergone or will undergo radical cystectomy, with or without lymphadenectomy or urethrectomy All possibles urinary diversion are included, like ileal conduit, neobladder etc...
Study: NCT06470399

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard therapy group
Description: Participants receive DS prescriptions from a physician based on current standard practices, which include biochemical markers, genetic data, and metabolic profiles.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: AI-Guided Group
Description: Participants receive DS prescriptions determined by GenAIS, is an AI system that considers genetic data, metabolic profiles, biochemical markers, and patient history.
Study: NCT05024305

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TWP-102 injection
Description: IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TWP-102 injection
Description: IV infusion
Study: NCT05340725

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DEX-IV
Description: patients will receive iv DEX 1µ/kg diluted in 100 ml saline and given slowly iv infusion over 10 min. 30 min. before induction of anesthesia.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DEX-Rectal
Description: Patients will receive rectal DEX suppository formulation at approximately 1µ/kg at 30 min. before induction of anesthesia

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DEX-Nano-Rectal
Description: Patients will receive rectal DEX suppository in the Niosomes formulation at approximately 1µ/kg at 30 min. before induction of anesthesia
Study: NCT05827055

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: 1000mg/m2 IV given days 1, 8, and 15 every 28 days (1 cycle)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: 1000mg/m2 IV given days 1, 8, and 15 every 28 days (1 cycle)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab paclitaxel
Description: 125 mg/m2 given days 1, 8, and 15 every 28 days (1 cycle)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab paclitaxel
Description: 125 mg/m2 given days 1, 8, and 15 every 28 days (1 cycle)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Proglumide
Description: Daily dose of 1200 mg orally given as 400 mg orally (PO), three times a day (TID) in vegan capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo given in vegan. capsules orally three times a day
Study: NCT05491252

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PAtient CEntered Self-Management Intervention (PACE-SMI)
Description: Week 1: General disease knowledge. Week 2: Role of self-care behaviors towards effective management of type 2 diabetes, motivational video and real story of a diabetic patient to serve as a role-model. Lastly, provision of diabetes self-care guidebook.~Week 3: Home visit to observe facilitators and barriers on initiating and maintaining behavioral change with social support as a key strategy.~Week 4: ECB session on Diet. Week 5: ECB session on Physical Activity. Week 6: ECB session on Foot Care. Week 7: ECB session on Medication Adherence. Week 8: Booster session comprising reflection, performance feedback and review of behavioral goals fostering continued performance accomplishment and addressing difficulties of maintaining behaviour change over time.
Study: NCT05665491

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HabitWorks
Description: Smartphone app-delivered interpretation bias intervention

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-Assessment
Description: Self-assessment of parenting behaviors and anxiety symptoms

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Self-Assessment
Description: Self-assessment of parenting behaviors and anxiety symptoms
Study: NCT01471314

Intervention type: BEHAVIORAL
Intervention: Headache day versus non-headache day
Study: NCT04849741

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: zilganersen
Description: zilganersen will be administered by ITB injection.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: zilganersen-matching placebo will be administered by ITB injection.
Study: NCT06490302

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lens A (ocufilcon D)
Description: 15 minutes of daily wear

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lens B (fanfilcon A)
Description: 15 minutes of daily wear
Study: NCT05171946

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S.opt.FL COVID-19 pDNA vaccine
Description: Low-Dose: (1mg) level

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S.opt.FL COVID-19 pDNA vaccine
Description: Mid-Dose: (2mg) level

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S.opt.FL COVID-19 pDNA vaccine
Description: High-Dose: (4mg) level
Study: NCT04137640

Intervention type: DRUG
Group type: OTHER
Intervention: palbociclib combined with letrozole
Description: Endocrine group will receive palbociclib combined with letrozole: palbociclib (Pfizer Manufacturing Deutschland GmbH, Freiburg, Germany; license number: H20180040) 125 mg/d, every 28 days as a cycle (medication for 3 consecutive weeks and withdrawal for 1 week); letrozole (Novartis Pharma Schweiz AG, Stein, Switzerland; license number: H20140149) 2.5 mg/d, for 6 consecutive months.

Intervention type: DRUG
Group type: OTHER
Intervention: epirubicin combined with cyclophosphamide and sequential docetaxel
Description: Chemotherapy group will receive epirubicin combined with cyclophosphamide and sequential docetaxel: epirubicin (Pfizer Wuxi Pharmaceutical Plant, Wuxi, China; license number: GYZZ H20000496), 90 mg/m2, intravenously, for 120 minutes, once every four weeks, totally four times; cyclophosphamide (Baxter Oncology GmbH, Halle, Germany; license number: H20160468), 600 mg/m2, once every four weeks, totally four times; sequential docetaxel (Sanofi-aventis Deutschland GmbH, Frankfurt am Main, Germany; license number: GYZZ J20150083) 75 mg/m2, intravenously, for 120 minutes, once every four weeks, totally four times.
Study: NCT04780646

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nature therapy in urban nature
Description: Nature therapy means visits in nature, actively perceiving the flora and fauna

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: City Walk
Description: City Walk means walking through urban surroundings (houses, streets, concrete..) with as little as possible contact to nature
Study: NCT05023863

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alpha Lipoic Acid 600 MG Oral Tablets
Description: Alpha Lipoic Acid (ALA) is a drug which has been used in treatment of diabetic neuropathy . It act through enhancing nitric oxide-mediated endothelium-dependent vasodilation, thus improving microcirculation in patients with diabetic polyneuropathy. It is considered a safe drug, generally with a daily dose of 200 to 2400 mg/day is considered tolerable without significant side effects. Only gastrointestinal tracts side effects like nausea, vomiting, dyspepsia and abdominal pain have been described in some clinical trials. Also FDA experts confirm its safety and efficacy in humans

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo tablets
Description: placebo tablets of the same generic of active drug which contain all the same ingredients as active tablets except alpha lipoic acid

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: radiation or concurrent chemoradiation
Description: radiation or concurrent radiotherapy plus platinum-based chemotherapy

Intervention type: RADIATION
Group type: PLACEBO_COMPARATOR
Intervention: radiation or concurrent chemoradiation
Description: radiation or concurrent radiotherapy plus platinum-based chemotherapy
Study: NCT05149027

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HBM4003 and Triprilimab
Description: Subjects will be treated with HBM4003 and Toripalimap on Day 1 during each 21-day cycles.
Study: NCT06191484

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: WELL Behavioral Probe
Description: Participant record the timing and regularity of sleep, meals, and social activity twice daily, for 3 months, using a digital diary. Participants also receive weekly motivational health coaching.
Study: NCT06231576

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Prehabilitation
Description: * Nutritional optimization: A nutritionist will perform a structured interview, comprehensive nutrition assessment, and provide personalized dietary advice. The main goal is to ensure optimal protein intake to support exercise-induced anabolism. A daily protein intake of 1.2-2.0 g/kg will meet needs as outlined in surgical nutrition guidelines.~* Exercise: Based on current guidelines and instructed by a dedicated physiotherapist, for 1 hour per day preoperatively to increase muscle strength, aerobic capacity and physical endurance. Intensity will be based on the rate of perceived exertion using the Borg scale, a 15-graded scale ranging from very light to very hard. Resistance exercises will target upper/lower body, and abdominal muscles.~* Psychological coaching and support: Performed as one interview during inclusion, followed by weekly phone calls by a study nurse coordinator during the preoperative intervention.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Prehabilitation
Description: * Nutritional optimization: A nutritionist will perform a structured interview, comprehensive nutrition assessment, and provide personalized dietary advice. The main goal is to ensure optimal protein intake to support exercise-induced anabolism. A daily protein intake of 1.2-2.0 g/kg will meet needs as outlined in surgical nutrition guidelines.~* Exercise: Based on current guidelines and instructed by a dedicated physiotherapist, for 1 hour per day preoperatively to increase muscle strength, aerobic capacity and physical endurance. Intensity will be based on the rate of perceived exertion using the Borg scale, a 15-graded scale ranging from very light to very hard. Resistance exercises will target upper/lower body, and abdominal muscles.~* Psychological coaching and support: Performed as one interview during inclusion, followed by weekly phone calls by a study nurse coordinator during the preoperative intervention.
Study: NCT05893784

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Use of progressive relaxation exercises education
Description: Progressive relaxation exercises education It starts with deep breathing exercises along with music. Then stretching and relaxation exercises are performed. After the education, an 8-minute video in which the progressive relaxation exercises was explained practically to the individuals was sent to their mobile phones. The participants were asked to perform these exercises regularly for 4 weeks, each day one hour before going to bed, simultaneously with the video.